Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2473-2481

  Lakhani, Sunil R ^a,b   Manek, Sanjiv ^c   Penault Llorca, Frederique ^d   Flanagan, Adrienne ^e   Arnout, Laurent ^f   Merrett, Samantha ^a   McGuffog, Lesley ^g   Steele, Dawn ^a   Devilee, Peter ^o   Klijn, Jan G M ^p   Meijers Heijboer, Hanne ^p   Radice, Paolo ^h   Pilotti, Silvana ^h   Nevanlinna, Heli ^w   Butzow, Ralf ^w,x   Sobol, Hagay ^q   Jacquemier, Jocylyne ^q   Lyonet, Dominique Stoppa ^u   Neuhausen, Susan L ^v   Weber, Barbara ^t   Wagner, Teresa ⁱ   Winqvist, Robert ^j   Bignon, Yves Jean ^d   Monti, Franco ^y   Schmitt, Fernando ^k   Lenoir, Gilbert ^l   Seitz, Susanne ^m   Hamman, Ute ⁿ   Pharoah, Paul ^s   Lane, Geoff ^r   Ponder, Bruce ^s   Bishop, D Timothy ^r   Easton, Douglas F ^g   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d CENTRE JEAN PERRIN   (France)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF VIENNA   (Austria)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k UNIVERSITY OF PORTO   (Portugal)

^l Hospices Civils de Lyon   (France)

^m MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^o LEIDEN UNIVERSITY   (Netherlands)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q INSTITUT PAOLI CALMETTES   (France)

^r ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^s CRUK Human Cancer Genetics Res Grp   (United Kingdom)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u INSTITUT CURIE   (France)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^x UNIVERSITY OF HELSINKI   (Finland)

^y Ospedale Infermi   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; ARTICLE; CANCER GRADING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LOGISTIC MODELS; MIDDLE AGED; MUTATION; ODDS RATIO; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144354423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1029-3     Document Type: Article

References (26)

1. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
2. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-30.
3. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68: 700-10.
4. Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999;65:1021-9.
5. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
6. Berchuck A, Heron KA, Carney ME, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-7.
7. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-11.
8. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999;59:868-71.
9. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (Bethesda) 1998;90: 1138-45.
10. Lakhani S, Easton D, Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-10.
11. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20: 2310-8.
12. Huber PJ. The behaviour of maximum likelihood estimates under nonstandard conditions. Proc Berkeley Symp Math Stat Probab 1967; 1:221-33.
13. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1994;54:54-8.
14. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Meo 1987;111:819-29.
15. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. Apmis 1991;99:353-8.
16. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer (Phila) 1998; 82:893-901.
17. Zweemer RP, Shaw PA, Verheijen RM, et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999;52:372-5.
18. Werness BA, Ramus SJ, Whittemore AS, et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000;31:1420-4.
19. Werness BA, Ramus SJ, Whittemore AS, et al. Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. Int J Gynecol Pathol 2000;19:390-4.
20. Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst (Bethesda) 1998;90:995-1000.
21. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283: 2260-5.
22. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397-404.
23. Ramus SJ, Bobrow LG, Pharoah PD, et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999;25:91-6.
24. Zweemer RP, Verheijen RH, Gille JJ, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol 1998;178:85-90.
25. Aida H, Takakuwa K, Nagata H, et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 1998;4:235-40.
26. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-6.